MedTrace Logo

Efficacy of MND-2119 in Participants With Hypertriglyceridemia

NCT03693131 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 580

Last updated 2019-08-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of MND-2119 compared to EPADEL CAPSULES 300 in participants with hypertriglyceridemia.

Conditions

  • Hypertriglyceridemia

Interventions

DRUG

Icosapent (MND-2119)

Icosapent (MND-2119) capsules.

DRUG

Icosapent (EPADEL CAPSULES 300)

Icosapent (EPADEL CAPSULES 300) capsules.

Sponsors & Collaborators

  • Mochida Pharmaceutical Company, Ltd.

    lead INDUSTRY

Principal Investigators

  • Kohichi Hayashi · Mochida Pharmaceutical Company, Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-27
Primary Completion
2019-06-15
Completion
2019-06-29

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03693131 on ClinicalTrials.gov